Disc Medicine: RALLY-MF Data Validates Pipeline Optionality

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.
Nasdaq

Disc Medicine, Inc. to Present Key Data from Hematology Portfolio at EHA 2025 Congress

Disc Medicine, Inc. announced it will present data from its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan from June 12-15, 2025. The presentations will ...
Nasdaq

Disc Medicine Highlights Positive Clinical Data for Bitopertin, DISC-0974, and DISC-3405 at EHA 2025; Management to Host Corporate Update Call

Disc Medicine announces positive updates on bitopertin, DISC-0974, and DISC-3405, with plans for upcoming clinical trials and data presentations. Disc Medicine, Inc. recently provided positive updates ...
Yahoo Finance

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Yahoo Finance

A Fresh Look at Disc Medicine’s Valuation After Bitopertin NDA Submission and Positive Phase 2 Data

Disc Medicine has submitted a New Drug Application to the FDA for bitopertin, seeking accelerated approval and priority review for erythropoietic protoporphyria in patients ages 12 and up. Positive ...
Seeking Alpha

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Quisel, CEO. Please go ahead. Good morning, and welcome to the ...